International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blastsHervé Dombret, Hartmut Döhner, Rajat Kumar et al.|Blood|2015Cited by 1.2k
Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional careHartmut Döhner, Hervé Dombret, Anna Dolnik et al.|Leukemia|2018Cited by 136
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimensJohn F. Seymour, Hervé Dombret, Hartmut Döhner et al.|BMC Cancer|2017Cited by 73